https://www.biopharmawatch.com/news/PHGE/biomx-waterio-zorronet-acquisition-update BiopharmaWatch en 2026-07-28T13:15:00.000Z BiomX And Water.IO Agree To Updated Zorronet Acquisition Terms https://www.biopharmawatch.com/news/XGN/exagen-participate-investor-conference-2026 BiopharmaWatch en 2026-07-28T13:09:05.687Z Exagen Inc. to Participate in Upcoming Investor Conference https://www.biopharmawatch.com/news/HCAT/midcap-advisors-health-catalyst-acquisition BiopharmaWatch en 2026-07-28T13:03:00.000Z MidCap Advisors Advises Leading Midwest Psychiatric Care Provider in Its Acquisition by Health Catalyst Capital https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-nicotinamide-riboside-aging-analysis BiopharmaWatch en 2026-07-28T12:32:00.000Z Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging https://www.biopharmawatch.com/news/MDLN/dentsply-sirona-expands-medline-sinclair-relationship BiopharmaWatch en 2026-07-28T12:30:00.000Z Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship https://www.biopharmawatch.com/news/ONMD/onemednet-secures-agreement-supply-real-world-data BiopharmaWatch en 2026-07-28T12:30:00.000Z OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-board-appointments BiopharmaWatch en 2026-07-28T12:30:00.000Z Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors https://www.biopharmawatch.com/news/CVRX/cvrx-presents-canaccord-growth-conference-2026 BiopharmaWatch en 2026-07-28T12:30:00.000Z CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference https://www.biopharmawatch.com/news/STIM/neuronetics-q2-2026-results-conference-call BiopharmaWatch en 2026-07-28T12:30:00.000Z Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call https://www.biopharmawatch.com/news/QTI/qt-imaging-israeli-health-registration BiopharmaWatch en 2026-07-28T12:30:00.000Z QT Imaging Receives Israeli Ministry of Health Regulatory Registration https://www.biopharmawatch.com/news/ANGO/angiodynamics-participate-upcoming-investor-conferences BiopharmaWatch en 2026-07-28T12:30:00.000Z AngioDynamics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-novel-endoxifen-compounds-breast-cancer BiopharmaWatch en 2026-07-28T12:30:00.000Z Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-bipin-dalmia-cbo BiopharmaWatch en 2026-07-28T12:30:00.000Z Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-q2-2026-financial-results BiopharmaWatch en 2026-07-28T12:13:25.652Z Nautilus Biotechnology Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LEGN/legend-biotech-investor-conference-call-q2-2026 BiopharmaWatch en 2026-07-28T12:06:48.768Z Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results https://www.biopharmawatch.com/news/RIGL/rigel-conference-call-q2-2026-results BiopharmaWatch en 2026-07-28T12:05:00.000Z Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-nasdaq-closing-bell-august-2026 BiopharmaWatch en 2026-07-28T12:01:00.000Z Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026 https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-fda-guidance-psychedelic-drug-development BiopharmaWatch en 2026-07-28T12:00:18.000Z Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development https://www.biopharmawatch.com/news/YDES/yd-bio-launches-cancer-testing-pilot-canada BiopharmaWatch en 2026-07-28T12:00:00.000Z YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada https://www.biopharmawatch.com/news/OSCR/oscar-health-2026-investor-day BiopharmaWatch en 2026-07-28T12:00:00.000Z Oscar Health, Inc. to Host 2026 Investor Day https://www.biopharmawatch.com/news/CODX/co-diagnostics-cosara-ebola-test-kits BiopharmaWatch en 2026-07-28T12:00:00.000Z Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies https://www.biopharmawatch.com/news/APYX/apyx-medical-participate-canaccord-growth-conference BiopharmaWatch en 2026-07-28T12:00:00.000Z Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/CRBP/corbus-fda-clearance-tempo-1-study-crb-701 BiopharmaWatch en 2026-07-28T12:00:00.000Z Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer https://www.biopharmawatch.com/news/PCRX/pacira-survey-impact-pain-americas-workforce BiopharmaWatch en 2026-07-28T12:00:00.000Z Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce https://www.biopharmawatch.com/news/LAB/standard-biotech-sale-mass-cytometry-illuminas-buyout BiopharmaWatch en 2026-07-28T12:00:00.000Z Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences https://www.biopharmawatch.com/news/ENLV/enlivex-announces-400-million-private-placement BiopharmaWatch en 2026-07-28T12:00:00.000Z Enlivex Announces $400,000,000 Private Placement https://www.biopharmawatch.com/news/PLUR/pluri-advances-commercial-expansion-cellav-uk-registration BiopharmaWatch en 2026-07-28T12:00:00.000Z Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK https://www.biopharmawatch.com/news/AIFF/firefly-next-health-precision-cognitive-health-initiative BiopharmaWatch en 2026-07-28T11:50:00.000Z Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides https://www.biopharmawatch.com/news/CMND/clearmind-medicine-phase-i-ii-trial-success BiopharmaWatch en 2026-07-28T11:47:00.000Z Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial https://www.biopharmawatch.com/news/LTRN/lantern-pharma-ema-phase-1b-2-trial-lp-184 BiopharmaWatch en 2026-07-28T11:45:00.000Z Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-fda-clearance-dyne-302-fshd BiopharmaWatch en 2026-07-28T11:30:00.000Z Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-patent-prevent-metastatic-recurrence BiopharmaWatch en 2026-07-28T11:30:00.000Z Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-q2-2026-financial-results-call BiopharmaWatch en 2026-07-28T11:30:00.000Z Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026 https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-symposium-2026-sno-asco-conference BiopharmaWatch en 2026-07-28T11:30:00.000Z Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q2-2026-earnings-call BiopharmaWatch en 2026-07-28T11:30:00.000Z Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-august-conferences BiopharmaWatch en 2026-07-28T11:30:00.000Z Trevi Therapeutics to Participate in Upcoming August Conferences https://www.biopharmawatch.com/news/NSRX/nasus-pharma-ceo-appointment-brendan-ogrady BiopharmaWatch en 2026-07-28T11:30:00.000Z Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth https://www.biopharmawatch.com/news/GH/guardant-health-patrick-dempsey-colorectal-cancer-tribute BiopharmaWatch en 2026-07-28T11:13:00.000Z Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer https://www.biopharmawatch.com/news/ALT/altimmune-positive-results-reclaim-trial-pemvidutide BiopharmaWatch en 2026-07-28T11:06:43.257Z Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-signs-new-customer-agreements BiopharmaWatch en 2026-07-28T11:05:00.000Z Lifecore Biomedical Signs Three New Customer Agreements https://www.biopharmawatch.com/news/INCY/incyte-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-28T11:00:00.000Z Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/ICLR/icon-anthropic-ai-collaboration-clinical-trials BiopharmaWatch en 2026-07-28T11:00:00.000Z ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials https://www.biopharmawatch.com/news/IQV/iqvia-reports-q2-2026-results BiopharmaWatch en 2026-07-28T11:00:00.000Z IQVIA Reports Second-Quarter 2026 Results https://www.biopharmawatch.com/news/ALKS/alkermes-q2-2026-financial-results BiopharmaWatch en 2026-07-28T11:00:00.000Z Alkermes plc Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OKYO/okyo-pharma-cso-share-purchase BiopharmaWatch en 2026-07-28T11:00:00.000Z OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer https://www.biopharmawatch.com/news/NRXS/neuraxis-q2-2026-results-business-update-call BiopharmaWatch en 2026-07-28T11:00:00.000Z NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026 https://www.biopharmawatch.com/news/RGEN/repligen-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-28T11:00:00.000Z Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance https://www.biopharmawatch.com/news/SNDX/syndax-announces-q2-2026-financial-results-call BiopharmaWatch en 2026-07-28T11:00:00.000Z Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 https://www.biopharmawatch.com/news/AVIR/ateas-bemnifosbuvir-ruzavir-phase-3-trial-results BiopharmaWatch en 2026-07-28T11:00:00.000Z Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-positive-fda-feedback-cln-049 BiopharmaWatch en 2026-07-28T11:00:00.000Z Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML https://www.biopharmawatch.com/news/ARVN/arvinas-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-28T11:00:00.000Z Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-fda-type-a-meeting-minutes BiopharmaWatch en 2026-07-28T11:00:00.000Z Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration https://www.biopharmawatch.com/news/INFU/infusystem-second-quarter-2026-results BiopharmaWatch en 2026-07-28T10:30:00.000Z InfuSystem to Report Second Quarter 2026 Financial Results on August 4, 2026 https://www.biopharmawatch.com/news/PMN/promis-neurosciences-positive-interim-results-pmn310 BiopharmaWatch en 2026-07-28T10:00:00.000Z ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial https://www.biopharmawatch.com/news/OLMA/login-guide-luckyniki-access-issues BiopharmaWatch en 2026-07-28T07:04:03.000Z Guida Al Login Su LuckyNiki E Soluzione Ai Problemi Di Accesso https://www.biopharmawatch.com/news/CGON/cg-oncology-bond-003-phase-3-results-lancet-oncology BiopharmaWatch en 2026-07-27T22:45:00.000Z CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology https://www.biopharmawatch.com/news/JNJ/johnson-johnson-talc-litigation-resolution BiopharmaWatch en 2026-07-27T22:31:00.000Z Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-emperor-heart-technology-embc-2026 BiopharmaWatch en 2026-07-27T21:11:00.000Z Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026 https://www.biopharmawatch.com/news/ATEC/atec-participation-upcoming-investor-conferences BiopharmaWatch en 2026-07-27T20:35:00.000Z ATEC Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AIDX/2020-biolabs-bio-asia-taiwan-strategy BiopharmaWatch en 2026-07-27T20:30:00.000Z 20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy https://www.biopharmawatch.com/news/STE/steris-conference-call-fiscal-2027-first-quarter BiopharmaWatch en 2026-07-27T20:30:00.000Z STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026 https://www.biopharmawatch.com/news/UHS/universal-health-services-q2-2026-financial-results BiopharmaWatch en 2026-07-27T20:16:00.000Z UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2026, AND REVISES 2026 FULL YEAR OPERATING RESULTS FORECAST https://www.biopharmawatch.com/news/ACH/accendra-health-leadership-appointments-it-procurement BiopharmaWatch en 2026-07-27T20:05:00.000Z Accendra Health Announces Leadership Appointments in IT and Procurement https://www.biopharmawatch.com/news/OPK/opko-health-q2-2026-results-highlights BiopharmaWatch en 2026-07-27T20:05:00.000Z OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results https://www.biopharmawatch.com/news/SCTX/scribe-therapeutics-ipo-2026 BiopharmaWatch en 2026-07-27T20:05:00.000Z Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement https://www.biopharmawatch.com/news/ORGO/organogenesis-affinity-trial-results-venous-leg-ulcers BiopharmaWatch en 2026-07-27T20:05:00.000Z Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers https://www.biopharmawatch.com/news/BNGO/bionano-report-q2-2026-financial-results BiopharmaWatch en 2026-07-27T20:05:00.000Z Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026 https://www.biopharmawatch.com/news/NYXH/nyxoah-q2-2026-financial-results-release BiopharmaWatch en 2026-07-27T20:05:00.000Z Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-webcast-conference-call-q2-2026 BiopharmaWatch en 2026-07-27T20:01:00.000Z Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates https://www.biopharmawatch.com/news/IMCC/im-cannabis-provides-corporate-update BiopharmaWatch en 2026-07-27T20:01:00.000Z IM Cannabis Provides Corporate Update https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q2-2026-results-report BiopharmaWatch en 2026-07-27T20:01:00.000Z Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-terence-rooney-cmo BiopharmaWatch en 2026-07-27T20:01:00.000Z Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer https://www.biopharmawatch.com/news/PMN/promis-neurosciences-webinar-precise-ad-trial-data BiopharmaWatch en 2026-07-27T20:00:00.000Z ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease https://www.biopharmawatch.com/news/BTMD/instamed-pharmaceuticals-ceo-appointment-launch-peptide-platform BiopharmaWatch en 2026-07-27T19:35:00.000Z Biotech Innovator InstaMed® Pharmaceuticals Appoints Tracy Gibbs, PhD, as Chief Executive Officer Ahead of Worldwide Launch of Non-Injectable Peptide Platform https://www.biopharmawatch.com/news/COSM/cosmos-health-ai-enabled-subscription-platform BiopharmaWatch en 2026-07-27T17:05:00.000Z Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels https://www.biopharmawatch.com/news/OLMA/betfirst-login-troubleshooting-netherlands BiopharmaWatch en 2026-07-27T16:53:33.000Z Betfirst Login Troubleshooting For Users In The Netherlands https://www.biopharmawatch.com/news/HCSG/pgp-welcomes-steven-grassa-managing-director BiopharmaWatch en 2026-07-27T16:10:00.000Z PGP Welcomes Steven Grassa as Managing Director to Deepen Healthcare Services Coverage https://www.biopharmawatch.com/news/CAPR/capricor-deramiocel-fda-advisory-meeting-update BiopharmaWatch en 2026-07-27T15:00:00.000Z Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel https://www.biopharmawatch.com/news/AVNS/american-industrial-partners-acquires-avanos-medical BiopharmaWatch en 2026-07-27T13:28:00.000Z American Industrial Partners Completes Acquisition of Avanos Medical, Inc. https://www.biopharmawatch.com/news/ACH/accendra-health-q2-2026-earnings-release-date BiopharmaWatch en 2026-07-27T13:15:00.000Z Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/CRIS/assurecare-curis-partner-rht-funding-infrastructure BiopharmaWatch en 2026-07-27T13:03:00.000Z AssureCare® and CURIS Partner to Ensure RHT Funding Builds Infrastructure That Outlasts the Program https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-ebola-ziare-d-mav-platform BiopharmaWatch en 2026-07-27T13:00:00.000Z Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-canaccord-genuity-conference-2026 BiopharmaWatch en 2026-07-27T12:32:00.000Z Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference https://www.biopharmawatch.com/news/ICCM/icecure-medical-choicestudy-breast-cancer BiopharmaWatch en 2026-07-27T12:32:00.000Z IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-ceo-appointment BiopharmaWatch en 2026-07-27T12:30:00.000Z Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-sonata-hcm-study-enrollment-completed BiopharmaWatch en 2026-07-27T12:30:00.000Z Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM) https://www.biopharmawatch.com/news/ENTX/entera-bio-private-placement-275-million BiopharmaWatch en 2026-07-27T12:30:00.000Z Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement https://www.biopharmawatch.com/news/SPRC/scisparc-targets-agentic-ai-market BiopharmaWatch en 2026-07-27T12:25:00.000Z SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity https://www.biopharmawatch.com/news/MDCX/medicus-pharma-fda-study-skinject-gorlin-syndrome BiopharmaWatch en 2026-07-27T12:17:00.000Z Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome https://www.biopharmawatch.com/news/VERU/veru-phase-2b-plateau-trial-enrollment-completed BiopharmaWatch en 2026-07-27T12:10:00.000Z Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss https://www.biopharmawatch.com/news/WAT/waters-launches-xevo-tq-absolute-xr-ivd-mass-spectrometer BiopharmaWatch en 2026-07-27T12:10:00.000Z Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-clinical-framework BiopharmaWatch en 2026-07-27T12:08:00.000Z bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung https://www.biopharmawatch.com/news/PLUR/pluristyx-partners-regenerative-medicine-hepatocyte-manufacturing BiopharmaWatch en 2026-07-27T12:07:00.000Z Pluristyx Partners With Leading Regenerative Medicine and Aerospace Pioneers to Standardize Clinical-Grade Hepatocyte Manufacturing for Space and Earth Applications https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-appoints-adrian-quartel-cmo BiopharmaWatch en 2026-07-27T12:00:00.000Z Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer https://www.biopharmawatch.com/news/ATRC/atricure-participate-investor-conferences BiopharmaWatch en 2026-07-27T12:00:00.000Z AtriCure to Participate at Upcoming Investor Conferences https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-aacr-conference-2026 BiopharmaWatch en 2026-07-27T12:00:00.000Z Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-appoints-debra-zack-cmo BiopharmaWatch en 2026-07-27T12:00:00.000Z Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer https://www.biopharmawatch.com/news/HUMA/humacyte-fda-acceptance-ind-ctev-cabg BiopharmaWatch en 2026-07-27T12:00:00.000Z Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting https://www.biopharmawatch.com/news/FRNM/freenome-simplescreen-crc-fda-approval-abbott-commercialization BiopharmaWatch en 2026-07-27T12:00:00.000Z FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-pcrx-201-manufacturing-transition BiopharmaWatch en 2026-07-27T12:00:00.000Z Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process https://www.biopharmawatch.com/news/KYTX/kyverna-elevatebio-manufacturing-agreement-miv-cel BiopharmaWatch en 2026-07-27T12:00:00.000Z Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel https://www.biopharmawatch.com/news/FBIO/fortress-biotech-urica-therapeutics-crystalys-financing BiopharmaWatch en 2026-07-27T12:00:00.000Z Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing https://www.biopharmawatch.com/news/LH/labcorp-launches-marker-genetic-health-panel BiopharmaWatch en 2026-07-27T12:00:00.000Z Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-appoints-michael-carrel-board BiopharmaWatch en 2026-07-27T12:00:00.000Z Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of Directors https://www.biopharmawatch.com/news/CTMX/cytomx-appoints-charles-fuchs-board-directors BiopharmaWatch en 2026-07-27T12:00:00.000Z CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-phase-3-yosemite-study-zodasiran BiopharmaWatch en 2026-07-27T11:30:00.000Z Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-first-patient-dosed-teluride-008 BiopharmaWatch en 2026-07-27T11:30:00.000Z Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/GLAS/glass-house-brands-dea-compliance-advisor BiopharmaWatch en 2026-07-27T11:30:00.000Z Glass House Brands Retains Former DEA Compliance Executive to Advise on Interstate Commerce and Export Opportunities https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-purpose-health-ai-leadership BiopharmaWatch en 2026-07-27T11:10:00.000Z Healthcare Triangle Creates "Purpose Health" to Monetize AI Demand and Accelerate Shareholder Returns https://www.biopharmawatch.com/news/DTIL/precision-biosciences-leadership-changes-clinical-milestones BiopharmaWatch en 2026-07-27T11:01:00.000Z Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones https://www.biopharmawatch.com/news/GKOS/glaukos-preserflo-microshunt-enrollment-completion BiopharmaWatch en 2026-07-27T11:00:00.000Z Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt https://www.biopharmawatch.com/news/VYNE/yarrow-bioscience-merger-vyne-therapeutics-phase-2-trial BiopharmaWatch en 2026-07-27T11:00:00.000Z Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease https://www.biopharmawatch.com/news/GOSS/gossamer-bio-fda-update-seralutinib-reacquisition BiopharmaWatch en 2026-07-27T11:00:00.000Z Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update https://www.biopharmawatch.com/news/AZN/astrazeneca-h1-q2-2026-results BiopharmaWatch en 2026-07-27T11:00:00.000Z AstraZeneca results: H1 and Q2 2026 https://www.biopharmawatch.com/news/BHVN/biohaven-yale-avilar-trade-secret-verdict BiopharmaWatch en 2026-07-27T11:00:00.000Z Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-positive-results-phase-2-zephyr-trial BiopharmaWatch en 2026-07-27T11:00:00.000Z MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-australian-regulatory-clearance-cmp-002 BiopharmaWatch en 2026-07-27T11:00:00.000Z CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder https://www.biopharmawatch.com/news/NMRA/neumora-nmra-215-toxicology-results-clinical-advancement-2026 BiopharmaWatch en 2026-07-27T11:00:00.000Z Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026 https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-advancement-vxa-222-program BiopharmaWatch en 2026-07-27T11:00:00.000Z VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb https://www.biopharmawatch.com/news/PMI/picard-medical-nyse-american-compliance-plan BiopharmaWatch en 2026-07-27T11:00:00.000Z Picard Medical Receives NYSE American Acceptance of Compliance Plan https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-07-27T11:00:00.000Z Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026 https://www.biopharmawatch.com/news/HROW/harrow-report-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-27T11:00:00.000Z Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 https://www.biopharmawatch.com/news/OKYO/okyo-pharma-btig-biotechnology-conference-2026 BiopharmaWatch en 2026-07-27T11:00:00.000Z OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 https://www.biopharmawatch.com/news/TDOC/teladoc-health-canada-accreditation-award BiopharmaWatch en 2026-07-27T10:45:00.000Z Teladoc Health Canada Achieves Accreditation Canada Primer Award, Advancing Quality Standards for Virtual and Hybrid Care in Canada https://www.biopharmawatch.com/news/KURA/kura-oncology-darlifarnib-cabozantinib-ccrcc-results BiopharmaWatch en 2026-07-27T10:32:00.000Z Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 https://www.biopharmawatch.com/news/ENSG/ensign-group-q2-2026-results BiopharmaWatch en 2026-07-27T10:04:00.000Z The Ensign Group Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-ide892-phase-1-2-expansion BiopharmaWatch en 2026-07-27T10:00:00.000Z IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers https://www.biopharmawatch.com/news/PFSA/profusa-management-changes-acquisition-term-sheet BiopharmaWatch en 2026-07-27T10:00:00.000Z Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company https://www.biopharmawatch.com/news/LEGN/legend-biotech-ceo-transition BiopharmaWatch en 2026-07-27T10:00:00.000Z Legend Biotech Announces CEO Transition https://www.biopharmawatch.com/news/OLMA/fatpirate-bonus-wagering-requirements-dutch-players BiopharmaWatch en 2026-07-27T09:28:51.000Z Fatpirate Bonus Wagering Requirements For Dutch Players https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-07-27 BiopharmaWatch en 2026-07-27T07:15:36.214Z Biotech Catalysts to Watch: Key Developments for 2026 and Beyond https://www.biopharmawatch.com/news/ARGX/argenx-acquires-forte-biosciences-immunology-pipeline BiopharmaWatch en 2026-07-27T05:07:00.000Z argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline https://www.biopharmawatch.com/news/FBRX/argenx-acquires-forte-biosciences-anti-cd122-antibody BiopharmaWatch en 2026-07-27T05:00:00.000Z argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline https://www.biopharmawatch.com/news/MENS/jyong-biotech-bph-market-opportunity-licensing-partnerships BiopharmaWatch en 2026-07-27T00:00:00.000Z Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and... https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-ceo-dajun-yang-power-list-2026 BiopharmaWatch en 2026-07-26T23:30:00.000Z Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 https://www.biopharmawatch.com/news/RXST/rxsight-inducement-grants-nasdaq-listing-rules BiopharmaWatch en 2026-07-26T20:00:00.000Z RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-chmp-recommendation-ubeslo-evlarco BiopharmaWatch en 2026-07-26T17:59:00.000Z NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib) https://www.biopharmawatch.com/news/OLMA/5gringos-registration-steps-norway BiopharmaWatch en 2026-07-26T16:13:06.000Z 5Gringos Registration Steps For Players In Norway https://www.biopharmawatch.com/news/OLMA/amazon-slots-registration-steps-belgian-players BiopharmaWatch en 2026-07-26T16:09:31.000Z Amazon Slots Registration Steps For Belgian Players https://www.biopharmawatch.com/news/OLMA/resolving-cashpot-login-issues-dutch-players BiopharmaWatch en 2026-07-26T15:38:54.000Z Resolving Cashpot Login Issues For Dutch Players https://www.biopharmawatch.com/news/OLMA/spinshouse-login-troubleshooting-netherlands-players BiopharmaWatch en 2026-07-26T15:32:46.000Z Spinshouse Login Troubleshooting For Netherlands Players